药物治疗对女性淋巴瘤患者生殖功能保护作用的研究进展
首都医科大学, 基础医学院, 北京 100069
| 摘 要： | 淋巴瘤是好发于年轻群体的恶性血液系统肿瘤。因淋巴瘤的常规化疗过程会对患者的生殖功能产生不可忽视的负面影响，随着当前淋巴瘤患者生存期的延长，生殖保护已逐渐成为讨论热点。目前临床常见的针对女性患者的生殖保护方式有胚胎冷冻技术、卵母细胞冷冻技术、卵巢组织冷冻技术和药物保护疗法等。其中药物保护疗法拥有广泛的适用范围，这得益于其经济且便于实施的优点。该疗法主要应用包括促性腺激素释放激素激动剂和拮抗剂在内的性腺功能相关激素类似物，以期延缓患者卵巢早衰的进程，进而维护远期生殖潜能。尽管大部分实验认为其具有明确的保护生殖能力的作用，仍有一些临床研究对此持有不同意见，特别是面对需进行造血干细胞移植的高危患者群体。本文旨在对药物生殖保护治疗在临床应用的现状进行总结，为有生殖需求的淋巴瘤患者提供远期生殖保护方面的思路。 |
| 关 键 词： | 淋巴瘤; 生殖保护; 促性腺激素释放激素激动剂; 促性腺激素释放激素拮抗剂 |
| DOI： | 10.57237/j.mrf.2023.02.004 |
View:
Downloads:
收稿日期: 2023-04-22
接受日期: 2023-05-23
在线出版日期: 2023-06-15
Research Progress of Protective Effect of Drug Therapy on Fertility in Female Patients with Lymphoma
School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China
| Abstract: | Lymphoma is a common hematological malignancy in young population. During the treatment of lymphoma, the gonadal damage caused by chemotherapy cannot be ignored for the reverse impact on the reproductive function of the patients during survivorship. As the survival period of lymphoma patients has increasingly extended, fertility preservation is now a hot topic. Fertility preservation methods for female patients currently include embryo cryopreservation, oocyte cryopreservation, ovarian tissue cryopreservation, pharmacological protection therapy, etc. Among them, pharmacological protection therapy has a wide range of applications thanks to its cheapness and easy implementation. It is based on the use of gonadal function-related hormone analogues, including gonadotropin-releasing hormone agonists and antagonists, with the effort to slow down the progression of premature ovarian failure and thus preserve the long-term reproductive potential. Although most studies suggest that it has a clear reproductive protective effect, there are still some research results that hold different opinions, especially for high-risk patients requiring hematopoietic stem cell transplantation. This article aims to summarize the current status of clinical application of drug reproductive protection therapy and provide ideas for long-term reproductive protection for lymphoma patients with reproductive needs. |
| Keywords: | Lymphoma; Fertility Preservation; Gonadotropin-Releasing Hormone Agonist; Gonadotropin-Releasing Hormone Antagonist |
参考文献
| [1] | HUTCHCRAFT M L, MCCRACKEN K, WHITESIDE S, et al. Current Fertility Preservation Options for Female Patients With Hodgkin Lymphoma [J]. Obstet Gynecol Surv, 2020, 75 (11): 683-91. |
| [2] | OKTAY K, HARVEY B E, PARTRIDGE A H, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update [J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2018, 36 (19): 1994-2001. |
| [3] | VIVIANI S, DELLINO M, RAMADAN S, et al. Fertility preservation strategies for patients with lymphoma: a real-world practice survey among Fondazione Italiana Linfomi centers [J]. Tumori, 2022, 108 (6): 572-7. |
| [4] | HARADA M, OSUGA Y. Fertility preservation for female cancer patients [J]. International journal of clinical oncology, 2019, 24 (1): 28-33. |
| [5] | BASSAN R, BRUGGEMANN M, RADCLIFFE H S, et al. A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia [J]. Haematologica, 2019, 104 (10): 2028-39. |
| [6] | SALAMA M, ISACHENKO V, ISACHENKO E, et al. Advances in fertility preservation of female patients with hematological malignancies [J]. Expert review of hematology, 2017, 10 (11): 951-60. |
| [7] | ARAPAKI A, CHRISTOPOULOS P, KALAMPOKAS E, et al. Ovarian Tissue Cryopreservation in Children and Adolescents [J]. Children, 2022, 9 (8): 1256. |
| [8] | BLUMENFELD Z, PATEL B, LEIBA R, et al. Gonadotropin-releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation [J]. Fertility and sterility, 2012, 98 (5): 1266-70 e1. |
| [9] | GLODE L M, ROBINSON J, GOULD S F. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone [J]. Lancet, 1981, 1 (8230): 1132-4. |
| [10] | ATAYA K, RAO L V, LAWRENCE E, et al. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys [J]. Biol Reprod, 1995, 52 (2): 365-72. |
| [11] | PEREYRA PACHECO B, MENDEZ RIBAS J M, MILONE G, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report [J]. Gynecologic oncology, 2001, 81 (3): 391-7. |
| [12] | FALORIO S, BIASOLI I, LUMINARI S, et al. Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions [J]. Hematological oncology, 2013, 31 (2): 72-8. |
| [13] | HUSER M, SMARDOVA L, JANKU P, et al. Fertility status of Hodgkin lymphoma patients treated with chemotherapy and adjuvant gonadotropin-releasing hormone analogues [J]. Journal of assisted reproduction and genetics, 2015, 32 (8): 1187-93. |
| [14] | BLUMENFELD Z, ZUR H, DANN E J. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors [J]. The oncologist, 2015, 20 (11): 1283-9. |
| [15] | MUNSTER P N, MOORE A P, ISMAIL-KHAN R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer [J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2012, 30 (5): 533-8. |
| [16] | BLUMENFELD Z. Fertility Preservation Using GnRH Agonists: Rationale, Possible Mechanisms, and Explanation of Controversy [J]. Clinical medicine insights Reproductive health, 2019, 13: 1179558119870163. |
| [17] | BLUMENFELD Z, ECKMAN A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a [J]. Journal of the National Cancer Institute Monographs, 2005, (34): 40-3. |
| [18] | BLUMENFELD Z. Fertility Preservation in Women With Malignancy: Future Endeavors [J]. Clinical medicine insights Reproductive health, 2019, 13: 1-8. |
| [19] | CHECA M A, BRASSESCO M, SASTRE M, et al. Random-start GnRH antagonist for emergency fertility preservation: a self-controlled trial [J]. International journal of women's health, 2015, 7: 219-25. |
| [20] | MEIROW D, ASSAD G, DOR J, et al. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice [J]. Human reproduction, 2004, 19 (6): 1294-9. |
| [21] | 彭萍, 莫亚勤, 杨传红, 等. GnRH类似物对化疗大鼠卵泡凋亡的影响 [J]. 中华妇产科杂志, 2010, 30 (1): 106-10. |
| [22] | DANFORTH D R, ARBOGAST L K, FRIEDMAN C I. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists [J]. Fertility and sterility, 2005, 83 (5): 1333-8. |
| [23] | PARLAKGUMUS H A, KILICDAG E B, BOLAT F A, et al. GNRH agonists and antagonists in rescue for cyclophosphamide-induced ovarian damage: friend or foe? [J]. Archives of gynecology and obstetrics, 2015, 291 (6): 1403-10. |
| [24] | VALSAMAKIS G, VALTETSIOTIS K, CHARMANDARI E, et al. GnRH Analogues as a Co-Treatment to Therapy in Women of Reproductive Age with Cancer and Fertility Preservation [J]. International journal of molecular sciences, 2022, 23 (4): 2287. |
| [25] | LI X, KANG X, DENG Q, et al. Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: a controlled experimental animal study [J]. Reproductive Biology and Endocrinology, 2013, 11: 16. |
| [26] | KNUDTSON J F, TELLEZ SANTOS M, FAILOR C M, et al. A Combination of a GnRH Antagonist and Agonist for Fertility Preservation in an Adolescent Female Murine Model [J]. Reproductive sciences, 2017, 24 (9): 1280-3. |
| [27] | MELI M, CARUSO-NICOLETTI M, LA SPINA M, et al. Triptorelin for Fertility Preservation in Adolescents Treated With Chemotherapy for Cancer [J]. J Pediatr Hematol Oncol, 2018, 40 (4): 269-76. |
| [28] | CHENG Y C, TAKAGI M, MILBOURNE A, et al. Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patients [J]. The oncologist, 2012, 17 (2): 233-8. |
| [29] | DIESCH T, ROVO A, VON DER WEID N, et al. Fertility preservation practices in pediatric and adolescent cancer patients undergoing HSCT in Europe: a population-based survey [J]. Bone marrow transplantation, 2017, 52 (7): 1022-8. |
